JP2014528914A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014528914A5 JP2014528914A5 JP2014519307A JP2014519307A JP2014528914A5 JP 2014528914 A5 JP2014528914 A5 JP 2014528914A5 JP 2014519307 A JP2014519307 A JP 2014519307A JP 2014519307 A JP2014519307 A JP 2014519307A JP 2014528914 A5 JP2014528914 A5 JP 2014528914A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- tocotrienol
- aciduria
- tocotrienol quinone
- individual
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161505051P | 2011-07-06 | 2011-07-06 | |
| US61/505,051 | 2011-07-06 | ||
| PCT/US2012/045628 WO2013006737A1 (en) | 2011-07-06 | 2012-07-05 | Treatment of methylmalonic aciduria, isovaleric aciduria, and other organic acidurias with tocotrienol quinones |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017231924A Division JP2018030892A (ja) | 2011-07-06 | 2017-12-01 | メチルマロン酸尿症、イソ吉草酸尿症、および他の有機酸尿症のトコトリエノールキノンによる処置 |
| JP2019215845A Division JP2020029465A (ja) | 2011-07-06 | 2019-11-28 | メチルマロン酸尿症、イソ吉草酸尿症、および他の有機酸尿症のトコトリエノールキノンによる処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014528914A JP2014528914A (ja) | 2014-10-30 |
| JP2014528914A5 true JP2014528914A5 (enExample) | 2015-09-03 |
| JP6728520B2 JP6728520B2 (ja) | 2020-07-22 |
Family
ID=47437452
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014519307A Expired - Fee Related JP6728520B2 (ja) | 2011-07-06 | 2012-07-05 | メチルマロン酸尿症、イソ吉草酸尿症、および他の有機酸尿症のトコトリエノールキノンによる処置 |
| JP2017231924A Pending JP2018030892A (ja) | 2011-07-06 | 2017-12-01 | メチルマロン酸尿症、イソ吉草酸尿症、および他の有機酸尿症のトコトリエノールキノンによる処置 |
| JP2019215845A Withdrawn JP2020029465A (ja) | 2011-07-06 | 2019-11-28 | メチルマロン酸尿症、イソ吉草酸尿症、および他の有機酸尿症のトコトリエノールキノンによる処置 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017231924A Pending JP2018030892A (ja) | 2011-07-06 | 2017-12-01 | メチルマロン酸尿症、イソ吉草酸尿症、および他の有機酸尿症のトコトリエノールキノンによる処置 |
| JP2019215845A Withdrawn JP2020029465A (ja) | 2011-07-06 | 2019-11-28 | メチルマロン酸尿症、イソ吉草酸尿症、および他の有機酸尿症のトコトリエノールキノンによる処置 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20150057363A1 (enExample) |
| EP (1) | EP2729004B1 (enExample) |
| JP (3) | JP6728520B2 (enExample) |
| ES (1) | ES2795798T3 (enExample) |
| PT (1) | PT2729004T (enExample) |
| WO (1) | WO2013006737A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005033092A1 (en) | 2003-09-19 | 2005-04-14 | Galileo Pharmaceuticals, Inc. | Chroman derivatives |
| EA035619B1 (ru) | 2005-06-01 | 2020-07-16 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Композиции для использования в способе лечения митохондриальных нарушений |
| EP1986636B1 (en) | 2006-02-22 | 2013-04-24 | Edison Pharmaceuticals, Inc. | Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases |
| PL2220030T3 (pl) | 2007-11-06 | 2016-07-29 | Bioelectron Tech Corp | Pochodne 4-(p-chinonylo)-2-hydroksybutanamidu do leczenia chorób mitochondrialnych |
| EP2237664A4 (en) | 2008-01-08 | 2013-05-22 | Edison Pharmaceuticals Inc | (HET) ARYL-p-CHINONE DERIVATIVES FOR THE TREATMENT OF OCHONDRIAL DISEASES |
| WO2009111576A2 (en) | 2008-03-05 | 2009-09-11 | Edison Pharmaceuticals, Inc. | 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES |
| EP2303824B1 (en) | 2008-06-25 | 2015-03-25 | Edison Pharmaceuticals, Inc. | 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases |
| EP2344142B1 (en) | 2008-09-10 | 2024-06-26 | PTC Therapeutics, Inc. | Treatment of pervasive developmental disorders with redox-active therapeutics |
| CA2740773A1 (en) | 2008-10-14 | 2010-04-22 | Edison Pharmaceuticals, Inc. | Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells |
| WO2010051277A1 (en) | 2008-10-28 | 2010-05-06 | Edison Pharmaceuticals, Inc. | Process for the production of alpha-tocotrienol and derivatives |
| CA2777479C (en) | 2009-04-28 | 2017-10-17 | Ptc Therapeutics, Inc. | Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones |
| US9464016B2 (en) | 2011-06-14 | 2016-10-11 | Edison Pharmaceuticals, Inc. | Catechol derivatives for treatment of oxidative stress diseases |
| CA2842486C (en) | 2011-07-19 | 2022-09-06 | Edison Pharmaceuticals, Inc. | Methods for oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols |
| CA2883879A1 (en) | 2012-09-07 | 2014-03-13 | Edison Pharmaceuticals, Inc. | Quinone derivatives for use in the modulation of redox status of individuals |
| US9670170B2 (en) | 2013-03-15 | 2017-06-06 | Bioelectron Technology Corporation | Resorufin derivatives for treatment of oxidative stress disorders |
| US9868711B2 (en) | 2013-03-15 | 2018-01-16 | Bioelectron Technology Corporation | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
| JP2016515526A (ja) | 2013-03-15 | 2016-05-30 | エジソン ファーマシューティカルズ， インコーポレイテッド | 酸化ストレス障害の処置のためのアルキル−ヘテロアリール置換されたキノン誘導体 |
| US9296712B2 (en) | 2013-03-15 | 2016-03-29 | Edison Pharmaceuticals, Inc. | Resorufin derivatives for treatment of oxidative stress disorders |
| HUE058877T2 (hu) | 2014-12-16 | 2022-09-28 | Ptc Therapeutics Inc | (R)-2-hidroxi-2-metil-4-(2,4,5-trimetil-3,6-dioxociklohexa-1,4-dienil)butánamid polimorf és amorf alakjai |
| JP7117241B2 (ja) | 2015-12-16 | 2022-08-12 | ピーティーシー セラピューティクス， インコーポレイテッド | 混合されたトコール組成物からアルファ－トコトリエノールを富化するための改良された方法 |
| EP3389646A1 (en) | 2015-12-17 | 2018-10-24 | BioElectron Technology Corporation | Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
| WO2017184583A1 (en) * | 2016-04-19 | 2017-10-26 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Anaplerotic agents for treatment of disorders of propionate and long chain fat metabolism |
| JP2018083799A (ja) | 2016-11-15 | 2018-05-31 | バイオエレクトロン テクノロジー コーポレイション | ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩 |
| HUE066196T2 (hu) | 2018-10-17 | 2024-07-28 | Ptc Therapeutics Inc | 2,3,5-trimetil-6-nonilciklohexa-2,5-dién-1,4-dion alfa-szinukleinopátiák, tauopátiák és egyéb rendellenességek szuppresszálására és kezelésére |
| EP3937922A4 (en) * | 2019-03-14 | 2022-11-30 | Hemoshear Therapeutics, Inc. | Methods of treating organic acidemias |
| US12703697B2 (en) | 2019-07-09 | 2026-08-11 | Icagen, Llc | BCAT modulation |
| EP4366700A1 (en) | 2021-07-08 | 2024-05-15 | PTC Therapeutics, Inc. | Pharmaceutical compositions comprising 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0204232D0 (en) | 2002-02-22 | 2002-04-10 | Isis Innovation | Assay |
| DE60211875T2 (de) | 2002-07-01 | 2006-10-26 | Santhera Pharmaceuticals (Schweiz) Ag | Screeningverfahren und Verbindungen zur Behandlung von Friedreich ataxia |
| EP1587960A2 (en) * | 2003-01-30 | 2005-10-26 | Research Development Foundation | Methods and compositions for analysis of mitochondrial-related gene expression |
| EA035619B1 (ru) * | 2005-06-01 | 2020-07-16 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Композиции для использования в способе лечения митохондриальных нарушений |
| EP1749552A1 (en) * | 2005-07-29 | 2007-02-07 | Neuropharma S.A. | Use of collismycin and derivatives thereof as oxidative stress inhibitors |
| EA201101576A1 (ru) * | 2009-04-28 | 2012-04-30 | Эдисон Фармасьютикалз, Инк. | Лекарственная форма токотриенол хинонов для лечения офтальмических (глазных) заболеваний |
| CA2777479C (en) * | 2009-04-28 | 2017-10-17 | Ptc Therapeutics, Inc. | Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones |
| WO2011072281A1 (en) * | 2009-12-11 | 2011-06-16 | Ptc Therapeutics, Inc. | Methods for treating methylmalonic acidemia |
-
2012
- 2012-07-05 ES ES12807735T patent/ES2795798T3/es active Active
- 2012-07-05 PT PT128077351T patent/PT2729004T/pt unknown
- 2012-07-05 JP JP2014519307A patent/JP6728520B2/ja not_active Expired - Fee Related
- 2012-07-05 EP EP12807735.1A patent/EP2729004B1/en active Active
- 2012-07-05 US US14/130,903 patent/US20150057363A1/en not_active Abandoned
- 2012-07-05 WO PCT/US2012/045628 patent/WO2013006737A1/en not_active Ceased
-
2017
- 2017-12-01 JP JP2017231924A patent/JP2018030892A/ja active Pending
-
2018
- 2018-06-26 US US16/019,363 patent/US20180303770A1/en not_active Abandoned
-
2019
- 2019-11-28 JP JP2019215845A patent/JP2020029465A/ja not_active Withdrawn
-
2020
- 2020-09-17 US US17/024,664 patent/US20210145769A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Argilés et al. | Are there any benefits of exercise training in cancer cachexia? | |
| US20160166631A1 (en) | Nutraceutical combination for prevention and treatment of type 2 diabetes | |
| US9168308B2 (en) | Compositions and methods for nutritional supplementation | |
| JP2019210299A (ja) | ケルセチン配糖体を含有する筋萎縮抑制剤 | |
| Tolar et al. | Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels | |
| JP2012531411A5 (enExample) | ||
| JP2014513065A5 (enExample) | ||
| FI3426285T3 (fi) | Pegyloidun urikaasin formulaatioita ja annoksia | |
| BR112014027010A2 (pt) | uso de laquinimod de alta dose para tratamento de esclerose múltipla | |
| CA2909160A1 (en) | Formulations of oxabicycloheptanes and oxabicycloheptenes | |
| BR112013031117A8 (pt) | Scilo-inositol para o tratamento de transtornos comportamentais e psiquiátricos. | |
| EP2460522A3 (en) | Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases | |
| Chiu et al. | Augmentation strategies for clozapine-resistant patients with schizophrenia | |
| JP2008531602A (ja) | 抗癌特性を有する化合物 | |
| US11304923B2 (en) | Use of a benzoate containing composition to treat glycine encephalopathy | |
| CN105832724B (zh) | 吲哚醇在制备抗抑郁症药物中的用途 | |
| JP2008063322A (ja) | ＨＭＧ−ＣｏＡリダクターゼ阻害剤、トコフェロール類及びＣｏＱ１０を含有する医薬組成物 | |
| JP2011509257A5 (enExample) | ||
| JP2009522260A (ja) | メチシリン耐性黄色ブドウ球菌をオキサシリンに対し感作する組成物および方法 | |
| JP2008509877A (ja) | 通常、ビタミンｃ、マグネシウム、緑茶抽出物を含む心血管系疾患を抑制するための医薬調合物 | |
| Azmin et al. | Micronutrients and Parkinson’s Disease | |
| JP2016534024A (ja) | 熱産生を増大させることができる組成物およびその使用 | |
| Thestrup-Pedersen | 8. Treatment strategies and compliance for the adult patient with atopic eczema | |
| CN104540509A (zh) | 用于肝脏再生的药物组合物 | |
| Sierra-Hoffman et al. | Daptomycin and ampicillin combination for treatment of enterococcus faecalis endocarditis |